此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)

2026年11月12日 更新者:GlaxoSmithKline

A Phase 3 Randomized Open-Label Study to Evaluate the Safety and Efficacy of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive type of lung cancer. Current treatment options are limited, and response to treatment may not last long. Outcomes are especially poor when the cancer has spread to the brain. This study tests whether a new treatment: risvutatug rezetecan (Ris-Rez) with atezolizumab works better than standard of care treatment. Ris-Rez is designed to deliver cancer-killing medicine directly to cancer cells. Atezolizumab helps the immune system attack cancer cells. Researchers will see if this combination helps people live longer and keeps the cancer from getting worse.

研究概览

研究类型

介入性

注册 (估计的)

700

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent form (ICF).
  • Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) at initial diagnosis and at trial entry and has received no prior systemic therapies for SCLC, with 1 exception where participants who have received one cycle of etoposide and carboplatin with or without atezolizumab are eligible
  • Is capable of giving signed informed consent including compliance with the requirements and restrictions listed in the ICF and protocol.
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Has adequate organ function.

Exclusion Criteria:

  • Has symptomatic central nervous system (CNS) metastases, CNS metastases with hemorrhagic features, or leptomeningeal disease.
  • Has known allergy or hypersensitivity to study intervention components or excipients.
  • Has any evidence of current interstitial lung disease or non-infectious pneumonitis or a prior history of interstitial lung disease (ILD) or non-infectious pneumonitis requiring high dose steroids or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging.
  • Has moderate to severe pulmonary disease or current clinically significant pulmonary compromise that, in the investigator's judgment, could jeopardize safety or study conduct.
  • Has clinically significant bleeding symptoms, bleeding tumors, or significant bleeding tendency within 1 month prior to first dose.
  • Known active infectious diseases requiring systemic treatment or known human immunodeficiency virus (HIV).
  • Has received any prior systemic anticancer treatment for the disease under study.
  • Has received any prior therapy with a Topoisomerase-1 (TOP1i), including antibody-drug conjugates that are effectively loaded as TOP1i, or treatment targeting B7-H3.
  • Has severe, uncontrolled, or active cardiovascular disorders.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Ris-Rez + atezolizumab

Ris-Rez will be administered.

Atezolizumab will be administered.

有源比较器:Etoposide, carboplatin, atezolizumab ± lurbinectedin

Participants will receive etoposide, carboplatin, atezolizumab with or without lurbinectedin.

Carboplatin will be administered.

Atezolizumab will be administered.

Etoposide will be administered.

Lurbinectedin will be administered.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall survival (OS)
大体时间:Up to 50 months

OS is defined as the time from the date of randomization to the date of death due to any cause.

Up to 50 months
Progression-free survival (PFS) by Blinded independent central review (BICR) assessment
大体时间:Up to 50 months

PFS is defined as the time from the date of randomization to the date of first documented objective tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by BICR assessment or death from any cause, whichever occurs first.

Up to 50 months

次要结果测量

结果测量
措施说明
大体时间
Time to confirmed deterioration of disease-related symptoms and physical functioning
大体时间:Up to 63 months

Time from the date of randomization to the first confirmed clinically meaningful deterioration in disease related symptoms and physical functioning using validated questionnaires will be measured.

Up to 63 months
Brain PFS
大体时间:Up to 63 months

Brain PFS is defined as the time from the date of randomization to the date of first documented brain disease progression (PD) per modified Response assessment in neuro-oncology brain metastases (RANO-BM) by BICR assessment or death from any cause, whichever occurs first in participants with a presence of brain metastases at baseline.

Up to 63 months
PFS by Investigator Assessment
大体时间:Up to 63 months

PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first.

Up to 63 months
Objective response rate (ORR)
大体时间:Up to 63 months

ORR is defined as the percentage of participants with best overall confirmed response of either complete response (CR) or partial response (PR) per RECIST 1.1 by RECIST-BICR assessment.

Up to 63 months
Duration of response (DOR)
大体时间:Up to 63 months

DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first.

Up to 63 months
ORR for participants not receiving bridging cycle
大体时间:Up to 63 months

ORR is defined as the percentage of participants with best overall confirmed response of either CR or PR per RECIST 1.1 by RECIST-BICR assessment

Up to 63 months
DOR for participants not receiving bridging cycle
大体时间:Up to 63 months

DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first.

Up to 63 months
Participant reported experience on study treatment
大体时间:Up to 63 months

Number of participants who reported their experience with study treatment using validated questionnaires will be measured.

Up to 63 months
Time to worsening of participants overall quality of life
大体时间:Up to 63 months

Time from the date of randomization to the first confirmed clinically meaningful deterioration in overall quality of life using validated questionnaires will be measured.

Up to 63 months
Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs) by severity
大体时间:Up to 63 months
Up to 63 months
Number of participants with AEs leading to dose modifications or study intervention discontinuation
大体时间:Up to 63 months
Up to 63 months
Number of participants with changes in hematology parameters
大体时间:Up to 63 months
Up to 63 months
Observed pharmacokinetic concentration of Ris-Rez
大体时间:Up to 63 months
Up to 63 months
Number of participants with Antidrug antibody (ADA) and Neutralizing Antibody (NAb) against Ris-Rez
大体时间:Up to 63 months
Up to 63 months
Titres of ADA against Ris-Rez
大体时间:Up to 63 months
Up to 63 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:GSK Clinical Trials、GlaxoSmithKline

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月25日

初级完成 (估计的)

2031年2月24日

研究完成 (估计的)

2032年3月24日

研究注册日期

首次提交

2026年11月12日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD 共享时间框架

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD 共享访问标准

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅